Olmesartanmedoxomil/Amlodipin Arcana (Olmesartan Medoxomil, Amlodipine)

Olmesartanmedoxomil/Amlodipin Arcana is used in cardiovascular therapy, primarily targeting hypertension and related vascular conditions.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Chronic stable angina: improves myocardial oxygen supply by reducing afterload.
• Heart failure with reduced ejection fraction: supports blood pressure control as part of combination therapy.

• Olmesartan medoxil blocks the binding of angiotensin II to the AT1 receptor, preventing vasoconstriction and aldosterone release. Amlodipine inhibits calcium influx through L‑type channels in vascular smooth muscle, causing dose‑dependent arterial dilation. The combined actions produce additive reductions in peripheral resistance and blood pressure.

Adverse reactions may occur with any antihypertensive regimen and should be monitored during therapy.

Common Side Effects

• Dizziness or light‑headedness
• Peripheral edema
• Headache
• Flushing
• Fatigue
• Nausea

Serious or Rare Side Effects

• Angio‑edema involving the face, lips or tongue
• Severe hypotension leading to syncope
• Hepatic enzyme elevation
• Acute kidney injury
• Myocardial infarction in susceptible patients
• Severe allergic skin reactions (Stevens‑Johnson syndrome)

Before initiating therapy, clinicians should evaluate patient history and comorbid conditions.

• Renal impairment: adjust dose and monitor serum creatinine.
• Hepatic dysfunction: use with caution; monitor liver enzymes.
• Electrolyte disturbances: check potassium and sodium levels regularly.
• Concomitant diuretics: monitor for excessive blood pressure drop.
• Pregnancy: contraindicated in the second and third trimesters; avoid use.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Olmesartanmedoxomil/Amlodipin Arcana may interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of hyperkalaemia and renal failure.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase amlodipine levels.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• Lithium: monitor serum lithium levels for toxicity.
• Rifampicin: may reduce amlodipine concentrations, requiring dose adjustment.